Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$2.80M
Expense Ratio	0.59%
PE Ratio	25.21
Shares Out	130,000
Dividend (ttm)	$0.22
Dividend Yield	1.02%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	25.64%
1-Year Return	-13.20%

Volume	152
Open	21.98
Previous Close	21.62
Day's Range	21.98 - 21.98
52-Week Low	18.56
52-Week High	28.19
Beta	n/a
Holdings	27
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

70.21% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	14.02%
Novo Nordisk A/S	NVO	13.51%
Hims & Hers Health, Inc.	HIMS	7.54%
Innovent Biologics, Inc.	1801	5.69%
Chugai Pharmaceutical Co., Ltd.	4519	5.68%
Teva Pharmaceutical Industries Limited	TEVA	5.11%
West Pharmaceutical Services, Inc.	WST	4.83%
Roche Holding AG	ROG	4.64%
Pfizer Inc.	PFE	4.61%
AstraZeneca PLC	AZN	4.59%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024